

**Interim results of Phase 1 clinical trial evaluating the 'PRIME' CAR-T cell therapy TAK-102 (NIB102) expressing IL-7/CCL19 in patients with GPC3 positive solid tumors were presented at the 37<sup>th</sup> Annual Meeting of the Society for Immunotherapy of Cancers**

We are pleased to announce that interim results of the first-in-human Phase 1 trial of TAK-102 (NIB102) sponsored by Takeda Pharmaceutical Company Limited ("Takeda"), a GPC3-targeted PRIME CAR-T cell<sup>1)</sup> immunotherapy, were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancers (SITC).

TAK-102 is an investigational therapy that originated from Noile-Immune and is equipped with PRIME technology. Takeda, through its subsidiary, holds an exclusive right to develop and commercialize TAK-102 worldwide.

<Summary of presentation>

TAK-102 is an autologous GPC3-targeted IL-7/CCL19-armed CAR T-cell immunotherapy for patients with GPC3-expressing solid tumors who are refractory or intolerant to standard treatments. Preliminary results from this Phase 1 study demonstrated an encouraging safety profile of TAK-102 and favorable cellular kinetic behavior at lower dose levels in patients with advanced solid tumors. The dose-escalation study is ongoing (NCT04405778).

- Of the four patients treated with TAK-102, no patient experienced dose-limiting toxicity, cytokine release syndrome, or neurotoxicity.
- Two patients achieved SD (Stable Disease)
- TAK-102 demonstrated favorable cellular kinetics behavior at lower dose levels with a dose-dependent increase in expansion and persistence.
- Promising TAK-102 activity signals were observed in soluble markers (AFP and LDH) and tumor microenvironment profiling when comparing patients with SD and PD (Progressive Disease).
- Additional patients are expected to be enrolled and evaluated.

**Noile-Immune Biotech, Inc., established as a university start-up, aims to contribute to the arrival of an era when we can overcome cancer through next-generation cancer immunotherapies, centering on PRIME technology.**

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech, Inc.

Department of Administration

E-mail: [ir@noile-immune.com](mailto:ir@noile-immune.com)

- 1) PRIME CAR-T cells: Proliferation-Inducing and Migration-Enhancing CAR-T cells, genetically modified to simultaneously produce interleukin-7 (IL-7) and CCL19.

The information contained in this press release material is solely based on the presentation made at the SITC and is subject to subsequent review as may be documented in the literature.

This press release material contains forward-looking statements, including statements regarding intent, belief or current expectations of Noile-Immune and/or its development partners. These forward-looking statements are based on the information available to Noile-Immune as of the date hereof as well as certain assumptions. Accordingly, such forward-looking statements are subject to various risks and uncertainties that may cause the actual results to significantly differ from those expressed or implied in such statements. Therefore, readers are advised not to place undue reliance on these forward-looking statements. The information in this press release is as of the date of this release (or otherwise specified dates), and Noile-Immune is under no obligation to regularly update the information herein.